Can we prevent Parkinson's disease?

被引：4

作者：

Swanson, Christine R. ^{[1
,2
]}

Sesso, Samantha L. ^{[1
]}

Emborg, Marina E. ^{[1
,2
,3
]}

机构：

[1] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Preclin Parkinsons Res Program, Madison, WI 53715 USA

[2] Univ Wisconsin, Neurosci Training Program, Madison, WI 53715 USA

[3] Univ Wisconsin, Dept Med Phys, Madison, WI 53715 USA

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2009年 / 14卷

基金：

美国国家卫生研究院;

关键词：

Parkinson's Disease; NSAIDS; Aging; Antioxidants; Pesticides; Neuroprotection; Alpha Synuclein; Review; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALPHA-SYNUCLEIN; NEUROTROPHIC FACTOR; MITOCHONDRIAL DYSFUNCTION; MICROGLIAL ACTIVATION; NIGROSTRIATAL SYSTEM; COENZYME Q(10); ANIMAL-MODELS; RISK-FACTORS; HEAD TRAUMA;

D O I：

10.2741/3331

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects 1 million people in the United States. Although the cause of PD remains unknown, a number of factors that increase the risk of developing this disease have been identified. Other factors that may prevent or slow down PD development and progression have also been found. In this review, we describe current basic, clinical and epidemiological findings on risk and neuroprotective factors and discuss how they can affect PD.

引用

页码：1642 / 1660

页数：19

共 196 条

[1] An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells [J].